Travere Therapeutics (TVTX) Receivables: 2014-2025
Historic Receivables for Travere Therapeutics (TVTX) over the last 12 years, with Sep 2025 value amounting to $84.5 million.
- Travere Therapeutics' Receivables rose 205.05% to $84.5 million in Q3 2025 from the same period last year, while for Sep 2025 it was $190.6 million, marking a year-over-year increase of 77.65%. This contributed to the annual value of $29.4 million for FY2024, which is 14.11% up from last year.
- Per Travere Therapeutics' latest filing, its Receivables stood at $84.5 million for Q3 2025, which was up 110.10% from $40.2 million recorded in Q2 2025.
- Travere Therapeutics' 5-year Receivables high stood at $84.5 million for Q3 2025, and its period low was $11.9 million during Q2 2021.
- Moreover, its 3-year median value for Receivables was $27.3 million (2024), whereas its average is $33.0 million.
- Its Receivables has fluctuated over the past 5 years, first decreased by 27.62% in 2021, then surged by 205.05% in 2025.
- Quarterly analysis of 5 years shows Travere Therapeutics' Receivables stood at $16.8 million in 2021, then climbed by 10.30% to $18.5 million in 2022, then spiked by 39.00% to $25.8 million in 2023, then rose by 14.11% to $29.4 million in 2024, then surged by 205.05% to $84.5 million in 2025.
- Its last three reported values are $84.5 million in Q3 2025, $40.2 million for Q2 2025, and $36.5 million during Q1 2025.